Hashimoto Yasuji, Wada Hiroshi, Kobayashi Shogo, Marubashi Shigeru, Eguchi Hidetoshi, Takeda Yutaka, Tanemura Masahiro, Umeshita Koji, Doki Yuichiro, Mori Masaki, Nagano Hiroaki
Dept. of Surgery, Graduate School of Medicine, Osaka University.
Gan To Kagaku Ryoho. 2010 Nov;37(12):2693-5.
We report a case of advanced hepatocellular carcinoma (HCC) successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic administration of interferon (IFN)-α and trans-arterial infusion (TAI) therapy of cisplatin (CDDP). A case was a 60-year-old man who had right upper abdominal pain and back pain. The abdominal CT revealed an early enhanced lesion in the posterior segment of the liver with portal vein and inferior vena caval tumor thrombi and multiple intrahepatic metastases. Tumor markers were elevated, AFP 2,480 ng/mL, PIVKA-II 31,900 mAU/mL. The patient underwent 4 courses of IFN-α/5-FU combination therapy and 8 times of TAI therapy of CDDP. After these therapies, tumors in the liver disappeared and tumor markers returned to the normal range. The patient is alive more than 58 months after the initial treatment. This case suggests that some patients with advanced HCC with tumor thrombus can get a long-term survival when intrahepatic lesions are controlled by various therapies including IFN-α/5-FU combination therapy.
我们报告一例晚期肝细胞癌（HCC）患者，通过肝动脉灌注5-氟尿嘧啶（5-FU）联合全身应用干扰素（IFN）-α和顺铂（CDDP）经动脉灌注（TAI）治疗成功治愈。该病例为一名60岁男性，有右上腹疼痛和背痛症状。腹部CT显示肝脏后段有早期强化病灶，伴有门静脉和下腔静脉瘤栓以及多发肝内转移。肿瘤标志物升高，甲胎蛋白（AFP）为2480 ng/mL，异常凝血酶原（PIVKA）-II为31900 mAU/mL。患者接受了4个疗程的IFN-α/5-FU联合治疗以及8次CDDP的TAI治疗。经过这些治疗后，肝脏内的肿瘤消失，肿瘤标志物恢复到正常范围。患者在初始治疗后存活超过58个月。该病例表明，一些伴有瘤栓的晚期HCC患者，当通过包括IFN-α/5-FU联合治疗在内的各种疗法控制肝内病灶时，可以获得长期生存。
